MiNK Therapeutics (NASDAQ:INKT) vs. Acumen Pharmaceuticals (NASDAQ:ABOS) Head to Head Contrast

MiNK Therapeutics (NASDAQ:INKT) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Risk and Volatility

MiNK Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500.

Insider & Institutional Ownership

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 19.7% of MiNK Therapeutics shares are held by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares MiNK Therapeutics and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-189.14%
Acumen Pharmaceuticals	N/A	-32.99%	-27.99%

Valuation & Earnings

This table compares MiNK Therapeutics and Acumen Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$22.46 million	($0.39)	-1.88
Acumen Pharmaceuticals	N/A	N/A	-$52.37 million	($1.38)	-1.64

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for MiNK Therapeutics and Acumen Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	0	0	2	0	3.00
Acumen Pharmaceuticals	0	0	3	1	3.25

MiNK Therapeutics currently has a consensus price target of $6.50, suggesting a potential upside of 787.31%. Acumen Pharmaceuticals has a consensus price target of $9.00, suggesting a potential upside of 296.48%. Given MiNK Therapeutics’ higher probable upside, equities analysts plainly believe MiNK Therapeutics is more favorable than Acumen Pharmaceuticals.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.